Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

Trial Profile

Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Filanesib (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Dec 2016 Results of phase 1 part of this trial (n=14) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 16 May 2016 Status changed from not yet recruiting to recruiting.
    • 16 Sep 2015 Planned initiation date changed from 1 Apr 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top